These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 38885198)

  • 1. Lipid Nanoparticle with 1,2-Di-O-octadecenyl-3-trimethylammonium-propane as a Component Lipid Confers Potent Responses of Th1 Cells and Antibody against Vaccine Antigen.
    Kawai A; Noda M; Hirata H; Munakata L; Matsuda T; Omata D; Takemura N; Onoe S; Hirose M; Kato T; Saitoh T; Hirai T; Suzuki R; Yoshioka Y
    ACS Nano; 2024 Jul; 18(26):16589-16609. PubMed ID: 38885198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in quadrivalent influenza vaccine vaccinated mice.
    Jangra S; Lamoot A; Singh G; Laghlali G; Chen Y; Ye T; García-Sastre A; De Geest BG; Schotsaert M
    Front Immunol; 2024; 15():1370564. PubMed ID: 38711520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens.
    Swaminathan G; Thoryk EA; Cox KS; Meschino S; Dubey SA; Vora KA; Celano R; Gindy M; Casimiro DR; Bett AJ
    Vaccine; 2016 Jan; 34(1):110-9. PubMed ID: 26555351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
    Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Polymer Nanoparticle Polydimethyl Diallyl Ammonium Chloride as An Adjuvant Enhances the Immune Response of SARS-CoV-2 Subunit Vaccine.
    Ren L; Ouyang C; Zhao S; Zheng Q; Guo W; Fan B; Zhou J; Zhang W; Hu M; Li J; Li B
    Adv Healthc Mater; 2024 Jun; 13(15):e2304575. PubMed ID: 38436662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses.
    Alameh MG; Tombácz I; Bettini E; Lederer K; Sittplangkoon C; Wilmore JR; Gaudette BT; Soliman OY; Pine M; Hicks P; Manzoni TB; Knox JJ; Johnson JL; Laczkó D; Muramatsu H; Davis B; Meng W; Rosenfeld AM; Strohmeier S; Lin PJC; Mui BL; Tam YK; Karikó K; Jacquet A; Krammer F; Bates P; Cancro MP; Weissman D; Luning Prak ET; Allman D; Locci M; Pardi N
    Immunity; 2021 Dec; 54(12):2877-2892.e7. PubMed ID: 34852217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses.
    Shirai S; Kawai A; Shibuya M; Munakata L; Omata D; Suzuki R; Yoshioka Y
    Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32756368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMART-lipid nanoparticles enabled mRNA vaccine elicits cross-reactive humoral responses against the omicron sub-variants.
    Mahalingam G; Rachamalla HK; Arjunan P; Karuppusamy KV; Periyasami Y; Mohan A; Subramaniyam K; M S; Rajendran V; Moorthy M; Varghese GM; Mohankumar KM; Thangavel S; Srivastava A; Marepally S
    Mol Ther; 2024 May; 32(5):1284-1297. PubMed ID: 38414245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel adjuvant G3 induces both Th1 and Th2 related immune responses in mice after immunization with a trivalent inactivated split-virion influenza vaccine.
    Hjertner B; Bengtsson T; Morein B; Paulie S; Fossum C
    Vaccine; 2018 May; 36(23):3340-3344. PubMed ID: 29706292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice.
    Song L; Xiong D; Hu M; Kang X; Pan Z; Jiao X
    PLoS One; 2016; 11(3):e0150678. PubMed ID: 26930068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice.
    Zhang J; Miao J; Han X; Lu Y; Deng B; Lv F; Zhao Y; Ding C; Hou J
    BMC Vet Res; 2018 Dec; 14(1):415. PubMed ID: 30577861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl-Dioctadecyl-Ammonium Bromide/Poly(lactic acid) Nanoadjuvant Enhances the Immunity and Cross-Protection of an NM2e-Based Universal Influenza Vaccine.
    Gao Y; Han S; Lu F; Liu Q; Yang J; Wang W; Wang Y; Zhang J; Ju R; Shen X; Zhao Y; Wang H; Tan W; Wang L
    ACS Nano; 2024 May; 18(20):12905-12916. PubMed ID: 38721835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus.
    Shirai S; Shibuya M; Kawai A; Tamiya S; Munakata L; Omata D; Suzuki R; Aoshi T; Yoshioka Y
    Front Immunol; 2019; 10():3018. PubMed ID: 31998305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses of mice to influenza subunit vaccine in combination with CIA07 as an adjuvant.
    Park SA; Song ES; Cho YJ; Ahn BY; Ha SH; Seong BL; Lee KH; Lee NG
    Microbiol Immunol; 2007; 51(11):1099-107. PubMed ID: 18037787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal nanoparticle-based conserved peptide influenza vaccine and monosodium urate crystal adjuvant elicit protective immune response in pigs.
    Dhakal S; Cheng X; Salcido J; Renu S; Bondra K; Lakshmanappa YS; Misch C; Ghimire S; Feliciano-Ruiz N; Hogshead B; Krakowka S; Carson K; McDonough J; Lee CW; Renukaradhya GJ
    Int J Nanomedicine; 2018; 13():6699-6715. PubMed ID: 30425484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix™ in VZV-primed mice.
    Luan N; Cao H; Wang Y; Lin K; Liu C
    Virol Sin; 2022 Oct; 37(5):731-739. PubMed ID: 35671982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.
    Svindland SC; Pedersen GK; Pathirana RD; Bredholt G; Nøstbakken JK; Jul-Larsen Å; Guzmán CA; Montomoli E; Lapini G; Piccirella S; Jabbal-Gill I; Hinchcliffe M; Cox RJ
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1181-93. PubMed ID: 23170900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
    Nishiyama A; Adachi Y; Tonouchi K; Moriyama S; Sun L; Aoki M; Asanuma H; Shirakura M; Fukushima A; Yamamoto T; Takahashi Y
    Vaccine; 2023 Jul; 41(31):4525-4533. PubMed ID: 37330368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.